Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Trading 06-10 15:29:48 EDT

1.73

-0.04

-2.02%

High1.86	Low1.72	Vol931.17K
Open1.76	D1 Closing1.77	Amplitude7.67%
Mkt Cap73.78M	Tradable Cap52.79M	Total Shares42.54M
T/O1.65M	T/O Rate3.06%	Tradable Shares30.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":1.7343,"timestamp":1781119695810,"preClose":1.77,"halted":0,"volume":931166,"delay":0,"changeRate":-0.020169491525423765,"floatShares":30437600,"shares":42541900,"eps":-1.71,"marketStatus":"Trading","change":-0.0357,"latestTime":"06-10 15:29:48 EDT","open":1.76,"high":1.86,"low":1.7243,"amount":1647710.9008576,"amplitude":0.076667,"askPrice":1.74,"askSize":196,"bidPrice":1.73,"bidSize":546,"shortable":3,"etf":0,"ttmEps":-1.71,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781121600000},"marketStatusCode":2,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":1.77,"preHourTrading":{"tag":"盘前","latestPrice":1.74,"preClose":1.77,"latestTime":"09:10 EDT","volume":46640,"amount":83910.16391999999,"timestamp":1781097008427,"change":-0.03,"changeRate":-0.016949,"amplitude":0.033898},"postHourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":1.77,"latestTime":"19:52 EDT","volume":144,"amount":253.6944,"timestamp":1781049150151,"change":-0.02,"changeRate":-0.011299,"amplitude":0.011299},"volumeRatio":0.805597,"impliedVol":0.528,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2639611591","title":"Annovis Bio: Buy Rating Reiterated as Late-Stage Neurodegenerative Pipeline Advances; $8 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2639611591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639611591?lang=en_us&edition=fundamental","pubTime":"2026-05-29 05:15","pubTimestamp":1780002924,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio, retaining the price target of $8.00. Jason McCarthy has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/annovis-bio-buy-rating-reiterated-as-late-stage-neurodegenerative-pipeline-advances-8-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/annovis-bio-buy-rating-reiterated-as-late-stage-neurodegenerative-pipeline-advances-8-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638511754","title":"Annovis Bio Regains Nyse Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2638511754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638511754?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA5BJRBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514586","title":"Annovis Bio Regains NYSE Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514586?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., May  26, 2026  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301048/0/en/Annovis-Bio-Regains-NYSE-Listing-Compliance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","AD","LU1169590202.USD","BK4139","NYSE","LU1169589451.USD","ANVS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363441","title":"Annovis Bio director Michael B Hoffman buys $141,027 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363441","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363441?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:12","pubTimestamp":1779408722,"startTime":"0","endTime":"0","summary":"Annovis Bio director Michael B. Hoffman reported open-market purchases of 76,344 common shares at prices ranging from USD 1.75 to USD 1.9.An additional 223,357 shares were reported as held indirectly through the 2024 Hoffman Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL39jCFH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio director Michael B Hoffman buys $141,027 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637541879","title":"Annovis Bio Announces Dilutive Equity Offering for Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2637541879","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637541879?lang=en_us&edition=fundamental","pubTime":"2026-05-21 06:05","pubTimestamp":1779314732,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has issued an announcement. On May 20, 2026, Annovis Bio entered an underwriting agreement with Canaccord Genuity for a pub...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-dilutive-equity-offering-for-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-dilutive-equity-offering-for-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","BK4139","BK4585","ANVS","BK4215","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636842010","title":"BRIEF-Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2636842010","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636842010?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:43","pubTimestamp":1779281029,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying WarrantsMay 20 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUAPJ225:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636684236","title":"Annovis Bio 7.9M share Spot Secondary priced at $1.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2636684236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636684236?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:20","pubTimestamp":1779279611,"startTime":"0","endTime":"0","summary":"The deal priced below last closing price of $1.94. Canaccord is acting as sole book running manager for the offering. Published first on TheFly – t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-7-9m-share-spot-secondary-priced-at-1-90-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-7-9m-share-spot-secondary-priced-at-1-90-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844339","title":"Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844339?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:00","pubTimestamp":1779278405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUAPJ225:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844332","title":"Annovis Bio Inc - Combined Offering Price per Share and Warrant Is $1.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844332?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:00","pubTimestamp":1779278405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUAPJ225:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636646768","title":"Annovis Bio announces common stock and warrants offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2636646768","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636646768?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:12","pubTimestamp":1779221537,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-common-stock-and-warrants-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-common-stock-and-warrants-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636861034","title":"Annovis Bio launches underwritten public offering of common stock with warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2636861034","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636861034?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:08","pubTimestamp":1779221310,"startTime":"0","endTime":"0","summary":"Annovis Bio launched a proposed underwritten public offering of common stock with accompanying warrants to purchase common stock.The common stock and warrants will be issued separately, but sold only as a combined package.Net proceeds are earmarked for continued Phase 3 development of buntanetap in Alzheimer’s disease, working capital, general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL2FYdNq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2T93.GBP","BK4139","IE00BGHQF748.EUR","BK4588","ANVS","BK4112","SG9999014005.SGD","LU0314104364.USD","BK4585","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636861761","title":"Annovis Bio Inc - Proceeds to Fund Phase 3 Buntanetap Development and General Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2636861761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636861761?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:06","pubTimestamp":1779221186,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUABJFQ3R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636686108","title":"Press Release: Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2636686108","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636686108?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:06","pubTimestamp":1779221160,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., May 19, 2026  -- Annovis Bio, Inc.  , a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease  and Parkinson's disease , today announced a proposed underwritten public offering in which it intends to offer and sell  shares of its common stock and  accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc.  is a Phase 3 clinical-stage biotechnology company developing treatments for neur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AD","ANVS","PD","BK4132","LU1169590202.USD","BK4023","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635080190","title":"Annovis Bio Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635080190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635080190?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:41","pubTimestamp":1778852460,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc reports results for the quarter ended December 31 - Earnings SummaryAnnovis Bio Inc ANVS.N reported a quarterly adjusted loss of 63 cents per share for the quarter ended December 31, l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089470","title":"Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089470","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089470?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:38","pubTimestamp":1778845135,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52592507/annovis-bio-q1-eps-0-63-misses-0-40-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635947089","title":"Annovis Bio Inc - Cash and Cash Equivalents $14.2 Mln as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635947089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635947089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA1JRDML:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089930","title":"Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089930","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089930?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"-- Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in. -- PD open-label extension  study: 40% of patients enrolled; full. -- New Drug Application  for buntanetap as a symptomatic treatment for. AD is expected in early 2027 and as a potential disease-modifying. \"We saw strong momentum across both our AD and PD programs in the first quarter,\" said Maria Maccecchini, Ph.D., President and CEO of Annovis. \"Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027. Simultaneously, we launched a PD OLE study and have been encouraged by the robust interest from both returning and new patients. This year is pivotal: we expect to generate substantive clinical data across both indications that will anchor our regulatory path toward an NDA submission for buntanetap.\". -- Screening: On May 15, 2026, Annovis closed enrollment to new partici","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","DBS","PD","AD","BK4139","LU1169589451.USD","BK4023","ANVS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633541554","title":"Annovis Bio Inc  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633541554","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633541554?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:38","pubTimestamp":1778247497,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc  expected to post a loss of39cents a share - Earnings Preview Annovis Bio Inc ANVS.N, ANVS.K is expected to  show no change in quarterly revenue when it reports  results on May 11 (est","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633308149","title":"Annovis Bio CEO presents multi-protein Alzheimer’s model at Fierce Biotech Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633308149","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633308149?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:32","pubTimestamp":1778153548,"startTime":"0","endTime":"0","summary":"Annovis to present at Fierce Biotech Week 2026 in Boston on May 13, 2026.CEO Maria Maccecchini scheduled to discuss a multi-protein model of Alzheimer’s disease, framing it as a rationale for the company’s buntanetap development program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5CNqj1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210150020.SGD","ANVS","SG9999014005.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4588","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2095319765.USD","LU0314104364.USD","BK4585","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662892","title":"Annovis Bio announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662892","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662892?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:28","pubTimestamp":1777584508,"startTime":"0","endTime":"0","summary":"Annovis Bio annual shareholder meeting scheduled for June 17, 2026, to be held virtually.Shareholders set to vote on election of five directors.Ballot includes ratification of Ernst & Young as independent auditor for fiscal 2026.Items also include amendment to 2019 Equity Incentive Plan to raise share reserve to 5,500,000 shares.Advisory votes planned on executive compensation, including preferred frequency of future say-on-pay votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLb98gQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.0484},{"period":"1month","weight":-0.2237},{"period":"3month","weight":-0.292},{"period":"6month","weight":-0.533},{"period":"1year","weight":-0.4216},{"period":"ytd","weight":-0.4884}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.132244},{"month":5,"riseRate":0.571429,"avgChangeRate":0.255652},{"month":6,"riseRate":0.428571,"avgChangeRate":0.132588},{"month":7,"riseRate":0.666667,"avgChangeRate":0.098191},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070358},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction